202 related articles for article (PubMed ID: 32433744)
1. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R; Cedena MT; Wong S; Shah N; Ríos-Tamayo R; Moraleda JM; López-Jiménez J; García C; Bahri N; Valeri A; Sánchez R; Collado-Yurrita L; Martin T; Wolf J; Lahuerta JJ; Martínez-López J
Blood Adv; 2020 May; 4(10):2163-2171. PubMed ID: 32433744
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
3. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Patel DA; Gopalakrishnan R; Engelhardt BG; McArthur E; Sengsayadeth S; Culos KA; Byrne M; Goodman S; Savani BN; Chinratanalab W; Jagasia M; Mosse CA; Cornell RF; Kassim AA
Bone Marrow Transplant; 2020 Jun; 55(6):1137-1146. PubMed ID: 31992845
[TBL] [Abstract][Full Text] [Related]
7. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
8. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
[TBL] [Abstract][Full Text] [Related]
9. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil.
Salgado ABDS; Magalhães RJP; Pontes RM; Barbosa EDS; Flores-Montero J; Sanoja-Flores L; Land MGP; Pimenta G; Dutra HDS; Costa ES; Orfao A; Maiolino A
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900396
[TBL] [Abstract][Full Text] [Related]
11. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma.
Cui QQ; Li ZH; Ma YP
Leuk Lymphoma; 2024 May; ():1-8. PubMed ID: 38814179
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
13. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
14. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
Martinez-Lopez J; Wong SW; Shah N; Bahri N; Zhou K; Sheng Y; Huang CY; Martin T; Wolf J
Blood Adv; 2020 Jul; 4(14):3295-3301. PubMed ID: 32706892
[TBL] [Abstract][Full Text] [Related]
15. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
16. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
17. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
18. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
D'Agostino M; Bertuglia G; Rota-Scalabrini D; Belotti A; Morè S; Corradini P; Oliva S; Ledda A; Grasso M; Pavone V; Ronconi S; Vincelli ID; Ballanti S; Velluti C; Cellini C; Gozzetti A; Palmas AD; Gamberi B; Mancuso K; Paris L; Zambello R; Petrucci MT; Bruno B; Musto P; Gay F
Blood; 2024 Feb; 143(7):592-596. PubMed ID: 38048557
[TBL] [Abstract][Full Text] [Related]
19. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC; Avet-Loiseau H; Anderson KC; Neri P; Paiva B; Samur M; Dimopoulos M; Kulakova M; Lam A; Hashim M; He J; Heeg B; Ukropec J; Vermeulen J; Cote S; Bahlis N
Blood Adv; 2020 Dec; 4(23):5988-5999. PubMed ID: 33284948
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Paiva B; Cedena MT; Puig N; Arana P; Vidriales MB; Cordon L; Flores-Montero J; Gutierrez NC; Martín-Ramos ML; Martinez-Lopez J; Ocio EM; Hernandez MT; Teruel AI; Rosiñol L; Echeveste MA; Martinez R; Gironella M; Oriol A; Cabrera C; Martin J; Bargay J; Encinas C; Gonzalez Y; Van Dongen JJ; Orfao A; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF;
Blood; 2016 Jun; 127(25):3165-74. PubMed ID: 27118453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]